• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.26% Nasdaq Down0.34%

    More On IPH.PA



    News & Info


    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Innate Pharma S.A. (IPH.PA)

    13.92 Up 0.49(3.65%) 9:05AM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Innate Pharma S.A.
    117, Avenue de Luminy
    BP 30191
    Marseille, 13009
    France - Map
    Phone: 33 4 30 30 30 30
    Fax: 33 4 30 30 30 00
    Website: http://www.innate-pharma.com

    Index Membership:N/A
    Full Time Employees:99

    Business Summary 

    Innate Pharma S.A., a biopharmaceutical company, is engaged in the research and development of pharmaceutical products primarily immunotherapy drug candidates for cancer and inflammatory diseases in France. The company develops monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its product candidates in clinical development comprise Lirilumab (IPH2102/BMS-986015), a monoclonal antibody (IgG4) blocking killer-cell immunoglobulin-like receptors in Phase II clinical trials for cancer and two Phase I clinical trials to solid tumors in combination with ipilimumab and nivolumab; and IPH2201, an IgG4 antibody, which is in Phase I clinical trials for the treatment of rheumatoid arthritis. The company is also involved in the pre-clinical development of IPH4102, a cytotoxic mAb that targets KIR3DL2. In addition, it is engaged in IPH33 program, a monoclonal antibody program that targets Toll-like Receptor-3 receptor, which is an inducer of Type I IFN and pro-inflammatory cytokines; and IPH43 program for the development of anti-MICA therapeutic antibody in oncology. It has licensing agreements with Bristol-Myers Squibb and Novo Nordisk A/S. Innate Pharma S.A. was founded in 1999 and is headquartered in Marseilles, France.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Innate Pharma S.A.

    Key Executives 
    Mr. Herv Brailly Ph.D., 53
    Co-Founder, Chairman of Exec. Board and Chief Exec. Officer
    Dr. Fran Romagn Ph.D., 51
    Co-Founder and Member of Scientific Advisory Board
    Mrs. Catherine Moukheibir MA, MBA, 56
    Exec. Vice-Pres, Sr. Advisor Fin. and Member of Exec. Board
    Mr. Nicolai Wagtmann Ph.D., 51
    Chief Scientific Officer, Exec. VP and Member of Exec. Board
    Mr. Laure-H Mercier MSc, MBA,
    Director of Investor Relations
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in EUR.